Journal
PHARMACOGENOMICS
Volume 11, Issue 4, Pages 471-474Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.10.11
Keywords
cancer; chemotherapy; genome-wide association study; pharmacogenomics
Categories
Funding
- NIH/NIGMS through the Pharmacogenetics of Anticancer Agents Research Group [U01GM61393]
- University of Chicago Breast Cancer SPORE [P50 CA125183]
- University of Chicago Cancer Center [P30 CA14599]
- NCI [RO1 CA 136765, R21 CA139278]
Ask authors/readers for more resources
Pharmacogenomics is emerging as an important component both in facilitating new drug development and in improving the utility of existing chemotherapeutic agents. Both candidate gene and genome-wide approaches have been used to identify genetic markers associated with chemotherapeutic response and/or toxicity. New molecular targeted agents have been designed based on a sophisticated understanding of the molecular alterations defining cancers. Over the next decade, the translation of these findings into clinical practice, as well as functional studies of genetic variants, is likely to take center stage. More comprehensive evaluation of the human genome, including the examination of rare SNPs, copy number variations, tandem repeats and epigenetic effects, will further improve our understanding of the relationship between genetics and drug response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available